SP4P Stock Overview
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Achieve Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.12 |
| 52 Week High | US$8.95 |
| 52 Week Low | US$2.84 |
| Beta | 1.28 |
| 1 Month Change | -2.95% |
| 3 Month Change | -11.70% |
| 1 Year Change | -43.63% |
| 3 Year Change | -54.78% |
| 5 Year Change | -94.71% |
| Change since IPO | -99.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| SP4P | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.4% | -0.2% | 0.5% |
| 1Y | -43.6% | -22.8% | 1.3% |
Return vs Industry: SP4P underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: SP4P underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| SP4P volatility | |
|---|---|
| SP4P Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SP4P has not had significant price volatility in the past 3 months.
Volatility Over Time: SP4P's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 22 | John Bencich | www.achievelifesciences.com |
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Achieve Life Sciences, Inc. Fundamentals Summary
| SP4P fundamental statistics | |
|---|---|
| Market cap | €144.96m |
| Earnings (TTM) | -€27.79m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.3x
P/E RatioIs SP4P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SP4P income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.82m |
| Earnings | -US$29.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -1,150.7% |
How did SP4P perform over the long term?
See historical performance and comparison